EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022)

Michael Pfaller, Michael Huband iD, Paul A Bien, Cecilia G Carvalhaes iD, Abby Klauer, Mariana Castanheira iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01132-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Michael Pfaller und 5 weiteren Autor:innen. Beteiligte Einrichtung: JMI Laboratories, North Liberty, lowa, USA. Hauptthemen laut MEDLINE: Triazoles, Antifungal Agents, Isoxazoles. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer (Davis).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Manogepix is a potent new antifungal agent targeting the fungal Gwt1 enzyme. Manogepix has previously demonstrated potent in vitro activity against clinical isolates of both Candida (except Candida krusei ) and Aspergillus species. This study determined the in vitro activity of manogepix and comparators against a large collection of infrequently encountered yeast and molds. Manogepix demonstrated potent in vitro activity against infrequently encountered yeasts exhibiting elevated MIC values to other drug classes, including Candida spp. (MIC 50/90 , 0.008/0.12 mg/L), Saprochaete clavata ( Magnusiomyces clavatus ) (MIC 50/90 , 0.03/0.06 mg/L), Magnusiomyces capitatus (MIC range , 0.016-0.06 mg/L), Rhodotorula minuta (MIC, 0.016 mg/L), and Rhodotorula mucilaginosa (MIC 50/90 , 0.03/0.12 mg/L). Similarly, manogepix was active against infrequently encountered mold isolates and strains exhibiting elevated MIC/MEC values to echinocandins, azoles, and amphotericin B, including Coprinopsis cinerea (MEC, 0.004 mg/L), Fusarium spp. (MEC 50/90 , 0.016/0.06 mg/L), Fusarium ( Gibberella ) fujikuroi species complex (MEC 50/90 , 0.016/0.03 mg/L), Lomentospora prolificans (MEC 50/90 , 0.03/0.06 mg/L), Microascus cirrosus (MEC, 0.008 mg/L), Paecilomyces spp. (MEC 50/90 , ≤0.008/0.016 mg/L), Pleurostomophora richardsiae (MEC, 0.06 mg/L), Sarocladium kiliense (MEC range, 0.016–0.12 mg/L), and Scedosporium spp. (MEC 50/90 , 0.03/0.06 mg/L). Manogepix demonstrated potent activity against a majority of the infrequently encountered yeast and mold isolates tested including strains with elevated MIC/MEC values to other drug classes. Additional clinical development of manogepix (fosmanogepix) in difficult-to-treat, resistant fungal infections is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesAntifungal AgentsIsoxazolesFungiAminopyridinesYeastsCandidaMicrobial Sensitivity Tests

Stichwörter der Autor:innen

manogepix SENTRY surveillancemoldsyeasts

Substanzen

APX001ATriazolesAntifungal AgentsAminopyridinesIsoxazoles

Autor:innen und Institutionen

  • JMI Laboratories, North Liberty, lowa, USA.
  • University of Iowa, Iowa City, lowa, USA.
  • PAB Pharma Consulting LLC, San Diego, California, USA.

ORCID-Profile: Michael Huband, Cecilia G Carvalhaes, Mariana Castanheira

Förderung

  • Pfizer (Davis)

Zitieren

APA

Pfaller, M., Huband, M., Bien, P. A., Carvalhaes, C. G., Klauer, A., & Castanheira, M. (2024). In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022). Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01132-23

Vancouver

Pfaller M, Huband M, Bien PA, Carvalhaes CG, Klauer A, Castanheira M. In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022). Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01132-23

BibTeX
@article{Pfaller2024,
  author = {Pfaller, Michael and Huband, Michael and Bien, Paul A and Carvalhaes, Cecilia G and Klauer, Abby and Castanheira, Mariana},
  title = {In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022)},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01132-23}
}
Kostenlos starten →